We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Google Builds AR Microscope for Cancer Detection

By LabMedica International staff writers
Posted on 25 Apr 2018
A team of researchers at Google LLC (Menlo Park, CA, USA) has developed a prototype Augmented Reality Microscope (ARM) platform that could help accelerate and democratize the adoption of deep learning tools for pathologists around the world. More...
The platform comprises a modified light microscope that allows for real-time image analysis and presentation of the results of machine learning algorithms directly into the field of view. The ARM can be retrofitted into existing light microscopes in hospitals and clinics using low-cost, readily available components, and without the need for analyzing whole slide digital versions of the tissue.

In a talk delivered at the Annual Meeting of the American Association for Cancer Research (AACR), with an accompanying paper "An Augmented Reality Microscope for Real-time Automated Detection of Cancer" (under review), Google described how its researchers demonstrated the potential utility of the ARM by configuring it to run two different cancer detection algorithms: one that detects breast cancer metastases in lymph node specimens, and another that detects prostate cancer in prostatectomy specimens. These models can run at magnifications between 4-40x, and the result of a given model is displayed by outlining detected tumor regions with a green contour. These contours help draw the pathologist’s attention to areas of interest without obscuring the underlying tumor cell appearance. While both cancer models were originally trained on images from a whole slide scanner with a significantly different optical configuration, the models performed remarkably well on the ARM with no additional re-training.

Google believes that the ARM has potential for a large impact on global health, especially for the diagnosis of infectious diseases, including tuberculosis and malaria, in developing countries. Additionally, even in hospitals that will adopt a digital pathology workflow in the near future, ARM could be used in combination with the digital workflow where scanners still face major challenges or where rapid turnaround is required (e.g. cytology, fluorescent imaging, or intra-operative frozen sections). The researchers will continue to explore how the ARM can help accelerate the adoption of machine learning for a positive impact around the world.

Related Links:
Google


Gold Member
Quality Control Material
iPLEX Pro Exome QC Panel
Online QC Software
Acusera 24•7
New
Food Allergy Screening ELISA Kit
Allerquant 14G B ELISA
New
Clinical Informatics Platform
CLARION™
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: Roche’s CE-Marked Elecsys pTau217 blood test is a single‑assay blood test measures phosphorylated tau 217, an indicator of amyloid pathology and a hallmark of Alzheimer’s disease (image credit: Shutterstock)

Blood-Based Alzheimer’s Test Gains CE Mark for Amyloid Pathology Detection

Alzheimer’s disease is the most common cause of dementia, yet confirmatory testing remains invasive and hard to access. Diagnosis currently takes an average of 3.5 years, and about 75% of people with dementia... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.